Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2025)

Neurocrine Biosciences' Gross Margin history spans 9 years, with the latest figure at 97.82% for Q4 2025.

  • For Q4 2025, Gross Margin fell 70.0% year-over-year to 97.82%; the TTM value through Dec 2025 reached 98.18%, down 38.0%, while the annual FY2025 figure was 98.18%, 38.0% down from the prior year.
  • Gross Margin reached 97.82% in Q4 2025 per NBIX's latest filing, roughly flat from 98.24% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 98.93% in Q2 2021 to a low of 76.0% in Q2 2022.
  • Average Gross Margin over 5 years is 97.15%, with a median of 98.39% recorded in 2025.
  • Peak YoY movement for Gross Margin: crashed -2293bps in 2022, then skyrocketed 2146bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 98.58% in 2021, then decreased by 0bps to 98.13% in 2022, then grew by 0bps to 98.35% in 2023, then rose by 0bps to 98.52% in 2024, then dropped by -1bps to 97.82% in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Gross Margin are 97.82% (Q4 2025), 98.24% (Q3 2025), and 98.36% (Q2 2025).